XPENG-MOTORS
20.5.2020 01:19:51 CEST | Business Wire | Press release
Xpeng Motors, a leading electric vehicle and technology company, today announced that it has received the official production license from China’s Ministry of Industry and Information Technology for its new own-built, wholly-owned factory, the Zhaoqing Xpeng Motors Intelligent Industrial Park in Guangdong Province.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200519005994/en/
The approval will accelerate the production of the super-long range sports sedan Xpeng P7, the company’s second production model, ensuring customer deliveries scheduled for 2Q 2020.
“The Zhaoqing manufacturing plant is an essential component of our vision to build a smart mobility ecosystem, from in-house R&D to smart manufacturing to customer services. Obtaining the production approval for the plant will hasten our progress in producing and delivering best-in-class products and services for our customers,” said He Xiaopeng, Chairman and CEO of Xpeng Motors.
“Our success in completing the Zhaoqing plant and rolling out our new P7 smart sedan despite the COVID-19 related challenges is further validation of the strength and robustness of our organization,” He said. The company has secured a sufficient stock of essential parts to ensure smooth manufacturing despite the disruption caused by the COVID-19 pandemic.
Located in Guangdong Province, the home-base of Xpeng Motors, the new Zhaoqing plant has a planned total area of 3,000 acres (2 million square meters), with vehicle production facilities covering some 1,500 acres (1 million square meters). Around 900 acres (600,000 square meters) of it has already been completed in the first phase.
After the foundation-laying in December 2017, the factory construction was completed in September 2019. Since then rigorous pre-production testing and small-scale trial production runs have verified the entire manufacturing process.
The Zhaoqing plant contains five workshops to cover the essential smart manufacturing functions, including stamping, welding, painting, assembly and battery pack production, as well as one battery assembly line, and is capable of manufacturing four different models. Serviced by 264 intelligent industrial robots, the Zhaoqing plant also incorporates dynamic test tracks covering 18 different types of test roads, and testing facilities for NVH, braking, vehicle seals and automatic parking systems.
The Zhaoqing plant is built in accordance with Industry 4.0 standards, with advanced MES manufacturing execution systems, Internet-of-Things technology, real-time production monitoring systems and a transparent manufacturing cycle, delivering the promise of a digital smart factory.
Xpeng has accumulated extensive experience through the production of the G3 smart SUV at the Zhengzhou plant, a partnership with Haima Automobile. By bringing manufacturing in-house, Xpeng is enhancing the autonomy, robustness, flexibility, cost-efficiency and intelligence of its vehicle production.
“The combination of end-to-end closed-loop R&D, smart manufacturing and quality customer services is our key differentiator. Today marks another milestone in Xpeng’s 6-year history, setting a solid foundation in pursuing our vision as a leader in the intelligent EV market,” Chairman He concluded.
For videos and images please visit:
https://drive.google.com/open?id=1mjds6n51HszTF5YhDcbaViucSwLjeiio
About XPENG Motors
Xpeng Motors is a leading Chinese electric vehicle company that designs and manufactures automobiles that are seamlessly integrated with the Internet and utilize the latest advances in artificial intelligence. The company's initial backers include its Chairman & CEO, He Xiaopeng, who’s also the co-founder of UCWeb Inc. and a former Alibaba executive. Established in 2014, Xpeng Motors has a senior management team with diverse backgrounds, including Co-founders Henry Xia and He Tao, both former senior executives at Guangzhou Auto with expertise in innovative automotive technology and R&D, and Vice Chairman & President Brian Gu, former Chairman of Asia Pacific Investment Banking at J.P. Morgan. It has received funding from strategic investors Alibaba Group and Xiaomi Corporation, as well as other prominent Chinese and international investors including IDG Capital, Morningside Venture Capital, GGV Capital and Primavera Capital. The company launched its first production model, the G3 SUV, in Dec 2018, and will launch its second production model, the P7 electric sports sedan, in April 2020 with deliveries to Chinese customers in Q2 2020. Xpeng Motors is headquartered in Guangzhou, China with offices in Beijing, Shanghai, Silicon Valley and San Diego in the U.S. and manufacture centers in Zhengzhou and Zhaoqing. For more information, please visit the official website: https://en.xiaopeng.com/
Follow us on social media for latest Xpeng news:
Facebook
Twitter
LinkedIn
YouTube
Instagram
View source version on businesswire.com: https://www.businesswire.com/news/home/20200519005994/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom